Figure 1

MMP-2 deficiency sensitizes human glioma xenograft cells to anoikis and inhibits tumor cell adhesion, invasion and migration. (a) The percentage of cell viability was determined with CytoTox-Glo Cytotoxicity Assay kit and the mean±S.E. values from three repetitions were plotted. Significant differences among different treatment groups were represented by *P<0.05 and **P<0.01. (b) Western blotting was performed using whole-cell lysates from adhered (Adh) and suspended (Sus) cells. GAPDH served as a loading control. (c) FACS analysis (10 000 events) with propidium iodide staining confirmed the enhanced anoikis sensitization in MMP2si-treated cells. Different phases of cell cycle in the histogram are represented by M1: sub-/G1, M2: G1, M3: S and M4: G2/M. The percent of apoptotic cells (sub-G1) was highlighted and experiment was repeated thrice to verify the results. (d) Percent of rounded cells were plotted as mean±S.E. obtained from three individual experiments (*P<0.01). (e) Cell adhesion experiments were performed on vitronectin (VN)- and fibronectin (FN)-coated plates as described in Materials and Methods. Percentage of cell adhesion was plotted as mean±S.E. obtained from three experimental replicates (*P<0.01). (f) Percentage of cell invasion through matrigel-coated transwells was depicted as mean±S.E. obtained from three independent experiments (*P<0.01). (g) Relative wound-healing migration distances were measured and plotted in the form of mean±S.E. values obtained from three replicates (*P<0.01). (h) Whole-cell lysates were subjected to western blotting